Latest Breaking News On - Nature reviews immunology - Page 6 : vimarsana.com

To Speed Vaccination, Some Call for Delaying Second Shots

To Speed Vaccination, Some Call for Delaying Second Shots Stretching the time between the first and second doses would greatly accelerate the rate at which people get at least partial protection. But some experts fear it could also lead to new variants. People without appointments waited outside a mass Covid vaccination site in Hagerstown, Md., this week.Credit...Chip Somodevilla/Getty Images April 9, 2021Updated 6:16 p.m. ET The prospect of a fourth wave of the coronavirus, with new cases climbing sharply in the Upper Midwest, has reignited a debate among vaccine experts over how long to wait between the first and second doses. Extending that period would swiftly increase the number of people with the partial protection of a single shot, but some experts fear it could also give rise to dangerous new variants.

XORTX Files New Provisional Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection

XORTX Therapeutics Inc.: XORTX Files New Provisional Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection

XORTX Therapeutics Inc.: XORTX Files New Provisional Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection CALGARY, AB / ACCESSWIRE / March 8, 2021 / XORTX Therapeutics Inc. XORTX" or the " Company") (CSE:XRX) (OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, with late-stage clinical programs, is pleased to announce the filing of a new provisional patent application entitled "Compositions and Methods for Enhancing Anti-Viral Therapies". This provisional patent was filed with the US Patent Office on Friday, March 5, 2021. In addition, studies of Coronavirus infections show that SARS and MERS and specifically COVID-19 can be frequently accompanied by pneumonia, acute kidney injury, proteinuria and hematuria

Towards an HIV Cure

Towards an HIV Cure MISSION: To drive concerted efforts to accelerate global scientific research and engagement towards a cure for HIV. The toolbox of interventions for fighting the global HIV pandemic has grown exponentially since the discovery of the virus, but a cure has remained beyond our grasp. In recent years, however, research to develop a cure for HIV or long-term remission has made promising progress, galvanizing researchers, advocates and community members alike. To that end, the mission of the IAS Towards an HIV Cure initiative is to drive concerted efforts to accelerate global scientific research and engagement towards a cure for HIV.

'Forestry owners need to get money in their pockets — that's what will keep the industry alive'

Farming Newsletter Enter email address Sign Up “It’s a small business for now, but I’ve built up a really nice set of customers in Westmeath, Dublin and Longford. They are happy with the product. “Before I started I had never held a chainsaw so it was very entertaining because I was with a group of guys and I really didn’t know what I was doing. I didn’t realise you needed to put chain oil in and I put the chain on backwards once too,” she laughed. While there aren’t many female chainsaw operators in traditional forestry, Olive has been “pleasantly surprised” at how people have responded, particularly her colleagues in the Westmeath Farm Forestry Group.

When Covid becomes a bad cold: Experts map the future of SARS-CoV-2

When Covid becomes a bad cold: Experts map the future of SARS-CoV-2 © Copyright (c) Daily Maverick , All Rights Reserved In the early days of the Covid-19 pandemic, many doctors, researchers, journalists and public health officials spent considerable energy describing how the SARS-CoV-2 virus was not “just another flu” but something far more deadly and debilitating. Now, with at least three effective vaccines being rolled out overseas and local vaccination programmes an ever-closer prospect, scientists are turning their attention to the long-term prospects of Covid-19. Nature Reviews Immunology, Marc Veldhoen of the University of Lisbon and J Pedro Simas of the Catholic University of Portugal draw on recent data that show that antibodies in people who have been infected by SARS-CoV-2, as well as those who have been vaccinated against it, persist for more than six months. After that people become increasingly vulnerable to reinfection.

When Covid becomes a bad cold: Experts map the future o...

Scientists predict the virus will be with us for the long run, but probably as just another common cold.